Investor Meet Company - Audio Archive

4BASEBIO outlines synthetic DNA platform, Phase 2 partnership, and path to cash flow positivity

40 min Listen to the original Episode page
BiotechnologyGene TherapySynthetic BiologyCDMOClinical TrialsCash FlowManufacturingIP

Summary

CEO Amy Walker and CFO Richard Bungie present 4BASEBIO's enzymatically produced synthetic DNA technology, positioning it as a faster, purer alternative to plasmid DNA for cell and gene therapy manufacturing. The company highlights a recent direct Phase 2 clinical supply agreement and partnerships with Genizon and TriLink Technologies. Management claims the technology supports over 120 customers and four INDs/CTAs, with a pipeline value exceeding £60 million. They project that achieving £21-22 million in annual revenue with 75% gross margins would make the business cash flow positive, citing upfront payments as a liquidity driver. The presentation also addresses H1 2026 overheads, attributing them to one-off GMP certification costs, and outlines a target steady-state cost base of £15-16 million.

Key takeaways

  1. 1
    also have a site in Madrid in Spain, which is focused on the production of the enzymes that we use within our manufacturing process. And that is actually a differentiated factor against some of our peers having control of that supply chain and their proprietary nature and their uses within our manufacturing process.

    Unidentified speaker (speaker_2) · 3:41

  2. 2
    Speed is incredibly important. When we think about plasma DNA, this could be in the range of four to six months to receive a plasma DNA suitable for clinical use. And we're billing for doing that in six to ten weeks. And in the case of personalized cancer vaccines, we believe that. we can deliver that product in less than three weeks.

    Unidentified speaker (speaker_2) · 6:11

  3. 3
    We disclosed at the half year for the first time the pipeline was more than 60 million of opportunity. But we don't see everything. And we believe by having partnerships with C DMOs, in particular, experts in this in the particular areas we're looking at. So Genison, very strong in viral vectors, trialing trilink very strong. in mRNA as examples, that we can leverage their pipelines as well and generate more inbound opportunities.

    Unidentified speaker (speaker_3) · 13:19

  4. 4
    Revenue recognition for personalized cancer vaccine opportunities is fundamentally different from standard deals, occurring on a per-batch basis due to the rapid, patient-specific nature of the therapy.

    Unidentified speaker (speaker_2) · 33:54

  5. 5
    The company identifies three large late-stage deals (valued at £1-7 million each) as a potential catalyst to achieve cash flow positivity, suggesting a lumpy deal flow profile rather than uniform early-stage contracts.

    Unidentified speaker (speaker_3) · 34:49

Episode sections

  1. 0:00 – 1:00

    Introduction and Disclaimer

    Speaker 0 provides standard legal disclaimers stating the presentation is for informational purposes only and does not constitute investment advice. Speaker 0 then introduces the platform, Investor Meet Company, and apologizes for the audio interruption before handing over to the presenter.

  2. 1:00 – 2:12

    Company Overview and Mission

    CEO Amy Walker introduces herself and CFO Richard Bungie, who joined in July 2026. Walker outlines the company's mission to enable clinical and commercial biomanufacturing of advanced therapies using enzymatically produced synthetic DNA, aiming to displace incumbent plasmid DNA technology. She notes the company was established in 2020 following the acquisition of its parent company, Expedium, by Abcam in late 2019.

  3. 2:12 – 3:23

    Technology Platform and IP

    Walker highlights the company's focus on deploying synthetic DNA technology across cell and gene therapy and vaccine manufacturing. Key metrics include serving over 120 customers, supporting four INDs/CTAs, holding 34 patent families, and employing around 120 people. The IP covers enzymes, manufacturing processes, and product claims in the UK and other jurisdictions.

  4. 3:23 – 4:40

    Global Operations and Workforce

    The company is headquartered in Cambridge, UK, with GMP-certified suites for clinical-stage production. A site in Madrid, Spain, produces proprietary enzymes, providing supply chain control. The workforce is described as scientifically minded, with 28% holding bachelor's degrees, 43% master's, and 12% PhDs, representing 23 nationalities.

  5. 4:40 – 9:11

    Synthetic vs. Plasmid DNA Benefits

    Walker compares synthetic DNA to plasmid DNA, citing cost-effectiveness, flexibility of scale (suitable for both large-scale and personalized therapies), speed (6-10 weeks vs. 4-6 months for plasmid), enhanced purity (no host cell contaminants), sequence agnosticism, and sustainability (reduced waste).

  6. 9:11 – 11:09

    Commercial Update and Recent Deals

    Walker reports on recent activities: her appointment as CEO in Feb 2026, facility expansion in Cambridge, launch of single-stranded DNA in May, and a clinical supply agreement for a Phase 2 trial (the first direct Phase 2 partnership). She also mentions partnerships with Genizon (viral vectors) and TriLink Technologies (cell therapy) in Aug/Sept 2026.

  7. 11:09 – 15:49

    Go-to-Market Strategy and Revenue Model

    CFO Richard Bungie outlines the GTM strategy, starting with preclinical research use only (RUO) from assemblers like Twist and Genscript, moving to clinical HQ and GMP grades. He notes a multi-channel approach involving direct sales and CDMO partnerships. Contract sizes range from £10-20k for RUO to seven figures for GMP.

  8. 15:49 – 33:11

    H1 2026 Performance and Pipeline

    Walker presents H1 2026 stats: 37 platform adoption evaluations, including work with three top-10 pharma companies and 19 biotech evaluations. She highlights a 55% conversion rate from RUO to HQ/GMP opportunities in 2026 and notes a shift in pipeline balance towards viral vectors and gene editing, though mRNA remains a significant value driver.

  9. 33:11 – 33:35

    Operational Scaling and MSA Execution

    Speaker 3 discusses the importance of engaging quality and legal teams to finalize Master Service Agreements (MSAs), noting that while MSA execution can be lengthy, subsequent opportunity addition is rapid once in place.

  10. 33:35 – 34:29

    Personalized Cancer Vaccine Delivery Model

    Speaker 2 outlines a model for personalized cancer vaccines where partners contract for clinical trials and require material delivery in under four weeks per patient, resulting in revenue recognition on a per-batch basis rather than standard terms.

  11. 34:29 – 35:29

    Revenue and Cash Flow Positivity Thresholds

    Speaker 3 states that achieving £21-22 million in annual revenue, assuming 75% gross margins and £15-16 million in cost space, would make the business cash flow positive, requiring approximately 20 early-stage GMP deals or three large late-stage deals.

  12. 35:29 – 36:35

    Upfront Cash Collections and Regulatory Visibility

    Speaker 3 notes that 30-50% of cash is typically received upfront, making individual opportunities cash flow positive despite revenue recognition occurring upon delivery. Speaker 2 confirms FDA audit expectations and potential public identification in approval documentation due to filed Drug Master Files.

  13. 36:35 – 38:52

    Competitive Positioning and Cost Base Reconciliation

    Speaker 2 attributes lost opportunities to customer funding constraints or program delays rather than product quality. Speaker 3 explains that high H1 2026 overheads were driven by one-off GMP license costs and rapid team expansion, with confidence in returning to a £15-16 million steady-state cost base.

  14. 38:52 – 40:10

    Closing Remarks and Capital Raise

    Speaker 2 expresses excitement following a recent capital raise and confidence in 2027, highlighting the company's role in genetic medicines. Speaker 1 concludes the session and redirects investors to a feedback form.

Claims worth verifying

FourBase Bio was established in 2020 following the acquisition of its parent company Expedium by Abcam at the end of 2019.

Unidentified speaker (speaker_2) ·1:56

How to verify: Company filings (e.g., UK Companies House records for incorporation date) and Abcam's historical acquisition announcements or investor presentations from 2019/2020. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

The company has served over 120 customers and supported four INDs or CTAs.

Unidentified speaker (speaker_2) ·2:31

How to verify: Company annual reports or investor presentations listing customer counts and clinical trial support milestones; regulatory databases (ClinicalTrials.gov) for IND/CTA references. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company holds 34 patent families governing its IP estate.

Unidentified speaker (speaker_2) ·2:52

How to verify: Patent databases (e.g., EPO, USPTO) search for assignee '4BASEBIO PLC' or related entities to count patent families. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company has around 120 employees, with 28% holding bachelor's degrees, 43% master's degrees, and 12% PhDs, representing 23 nationalities.

Unidentified speaker (speaker_2) ·2:52

How to verify: Company annual reports, ESG reports, or press releases detailing workforce statistics around November 2026. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Plasmid DNA manufacturing takes 4-6 months, while synthetic DNA takes 6-10 weeks.

Unidentified speaker (speaker_2) ·6:11

How to verify: Technical white papers or product data sheets from FourBase Bio comparing turnaround times; industry benchmarks for plasmid vs. synthetic DNA production. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

CEO Amy Walker was appointed in February 2026, having formerly served as COO.

Unidentified speaker (speaker_2) ·9:15

How to verify: Company press releases or regulatory filings (e.g., UK Companies House director appointments) confirming Amy Walker's appointment date and previous role. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

A clinical supply agreement was signed in May 2026 for a Phase 2 clinical trial.

Unidentified speaker (speaker_2) ·9:55

How to verify: Company press releases or regulatory filings announcing the specific Phase 2 partnership and supply agreement. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Partnerships with Genizon and TriLink Technologies were announced in August and September 2026.

Unidentified speaker (speaker_2) ·10:34

How to verify: Company press releases or regulatory filings detailing the collaboration agreements with Genizon and TriLink Technologies. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

The disclosed pipeline value exceeded £60 million at the half-year.

Unidentified speaker (speaker_3) ·13:19

How to verify: Company half-year financial results or investor presentations for H1 2026 disclosing pipeline value. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company raised close to £40 million in 2024 and completed a £15 million fundraise a few weeks prior to the November 2026 presentation.

Unidentified speaker (speaker_3) ·28:34

How to verify: Company regulatory filings (e.g., UK Companies House, stock exchange announcements) for the 2026 fundraising and the recent 2026 capital raise. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

MSAs can take a surprisingly long time to execute, but adding new opportunities is quick once in place.

Unidentified speaker (speaker_3) ·33:11

How to verify: Review company investor presentations or press releases detailing the timeline from MSA signing to first product delivery for recent clients. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Partners expect delivery of personalized cancer vaccine material in less than four weeks.

Unidentified speaker (speaker_2) ·33:54

How to verify: Check clinical trial protocols or partnership announcements for time-to-manufacturing metrics cited in recent deals. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Revenue for personalized vaccine opportunities is recognized on a per-batch basis.

Unidentified speaker (speaker_2) ·34:15

How to verify: Review the company's accounting policies in future financial statements or investor presentations regarding revenue recognition for custom manufacturing. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company targets a 75% gross margin.

Unidentified speaker (speaker_3) ·34:29

How to verify: Verify against the company's financial guidance documents or investor deck slides specifying margin targets. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company targets a steady-state cost space of £15-16 million.

Unidentified speaker (speaker_3) ·34:29

How to verify: Compare against the company's annual budget filings or investor presentations outlining operational cost targets. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

30-50% of cash is received upfront from customers.

Unidentified speaker (speaker_3) ·35:29

How to verify: Analyze cash flow statements or notes to financials for 'deferred revenue' or 'contract liabilities' and cash collection terms in client contracts. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company has a Drug Master File on file with the FDA.

Unidentified speaker (speaker_2) ·35:45

How to verify: Search the FDA Drug Master File database for entries associated with 4BASEBIO PLC or its parent/related entities. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

H1 2026 overheads were close to £9 million.

Unidentified speaker (speaker_3) ·37:15

How to verify: Review the company's interim financial report for the first half of 2026. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

GMP license costs were a significant one-off expense contributing to high H1 2026 overheads.

Unidentified speaker (speaker_3) ·37:55

How to verify: Examine the notes to the H1 2026 financial statements for specific line items related to certification or GMP compliance costs. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

The company recently announced a capital raise.

Unidentified speaker (speaker_2) ·39:10

How to verify: Search for press releases or regulatory filings (e.g., RNS in the UK) from 4BASEBIO PLC dated prior to November 2026 announcing equity or debt financing. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

Primary source

Do your own research

  • Verify the £60 million pipeline value against the company's latest interim or annual financial filings to confirm if these are signed contracts or indicative values.
  • Check the specific terms of the Phase 2 clinical supply agreement for exclusivity, milestone payments, and revenue recognition criteria.
  • Review the H1 2026 financial statements to isolate the one-off GMP license costs and assess the sustainability of the reported overheads.
  • Confirm the status of the 34 patent families and their jurisdictions to evaluate the strength of the IP moat against competitors like Twist Bioscience or Genscript.
  • Analyze the customer concentration risk by reviewing the top 10 customers in the latest annual report, noting the claim of working with three top-10 pharma companies.
  • Assess the cash flow model by reviewing the company's current cash runway and burn rate post-recent capital raise mentioned in the closing remarks.
  • Verify the FDA Drug Master File (DMF) status and any public identification in regulatory filings for partner programs to validate the visibility claim.
  • Compare the 6-10 week delivery claim against industry standards for plasmid DNA and other synthetic DNA providers to assess the validity of the speed advantage.
Full transcriptexpand
0:00
Unidentified speaker (speaker_0): All presentations are provided for informational purposes only. They do not serve as an invitation or encouragement to participate in any investment activities. If you are considering making an investment, you should seek appropriate financial advice.
0:16
Unidentified speaker (UNKNOWN): What
0:16
Unidentified speaker (speaker_0): you're about to listen to is an audio recording of a presentation originally broadcast on our platform. As such, sometimes presenters might refer to graphs. images, or videos.
0:29
Unidentified speaker (UNKNOWN): For
0:29
Unidentified speaker (speaker_0): the original presentation and much more, check out our website at investormeetcompany.com. Apologies for the interruption. Back to the presentation.
0:40
Unidentified speaker (UNKNOWN): Good
0:40
Unidentified speaker (speaker_1): afternoon, ladies and gentlemen. Welcome to the Four Base Bar PLC Investor presentation. Throughout today's recorded meeting, attendees will be in listen-only listen only mode. Questions are encouraged, they can be submitted at any time just using the QA tab situated. on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin we'd like to submit the following poll and I'm sure that the company be most grateful for your participation. I'd now like to hand
1:00
Unidentified speaker (speaker_1): over to CEO Amy Walker. Amy, good afternoon.
1:04
Unidentified speaker (speaker_2): Thank you very much and welcome everyone. Thank you for attending our investor meet company meeting in November 26. My name's name is Amy Walker. I'm the Chief Executive Officer of Forbase Forebase Bio and I will hand over to Richard who is a new face onto the ELT.
1:17
Unidentified speaker (speaker_3): Thanks, Amy. So Richard Bungie, Chief Financial Officer, delighted to join FourBase Bio in July this year and very pleased to be doing my first investment company presentation.
1:31
Unidentified speaker (UNKNOWN): So
1:31
Unidentified speaker (speaker_2): starting with FourBase Bio's mission statement, it's really about enabling clinical and commercial biomanufacturing of advanced therapies using. our enzymatically produced DNA. And really the objective there is to empower safer, faster, and more cost effective treatments to improve patient outcomes worldwide by displacing the incumbent technology plasma DNA,
1:51
Unidentified speaker (speaker_2): which we'll talk a little bit more about in the coming slides.
1:56
Unidentified speaker (speaker_2): As a reminder to some of you that are familiar with this story, and as an introduction to those that are less familiar, for ForBays Bio was established in 2020. So we're a relatively young company following the acquisition of our parent company Expedium to ABCAM at the end of 2019.
2:12
Unidentified speaker (UNKNOWN): And
2:12
Unidentified speaker (speaker_2): really since then, we have focused on deploying our synthetic DNA technology across the breadth of cell and gene therapy and vaccine manufacturing. And that involves the production of a number of different DNA molecules that really serve the broader genetic medicine space. Today we've served with over 120 customers, and very critically we have
2:31
Unidentified speaker (speaker_2): supported four INDs or CTAs. So this is customers that are using our products in clinical stage manufacturing across the breadth of different regulatory organizations, including here in the UK but also in the US. We have 34 patent families, which really govern uh the IP estate of the technology. And today we have around
2:52
Unidentified speaker (speaker_2): 120 employees.
2:58
Unidentified speaker (speaker_2): Speaking of that strong patent portfolio, uh, it really spans the breadth of our technology platform with a comprehensive and growing IP estate, which really starts with the enzymes, which are the critical ingredients that are used in the manufacturing of our DNA, and then it spans the different manufacturing processes that we deploy. to make our DNA molecules, ending with product claims
3:18
Unidentified speaker (speaker_2): here in the UK and in other jurisdictions.
3:23
Unidentified speaker (UNKNOWN): As
3:23
Unidentified speaker (speaker_2): everyone knows, we are a UK-based company. So we're headquartered here in Cambridge, where Richard and I sit. And we have three sites here. We have our headquarters facility, and then we have our GMP certified suites, which are responsible for the clinical stage production of our clients' process. programmes.
3:40
Unidentified speaker (UNKNOWN): We
3:41
Unidentified speaker (speaker_2): also have a site in Madrid in Spain, which is focused on the production of the enzymes that we use within our manufacturing process. And that is actually a differentiated factor against some of our peers having control of that supply chain and their proprietary nature and their uses within our manufacturing process.
3:58
Unidentified speaker (speaker_2): Over the course of the last 12 to 18 months, we have significantly expanded our global. commercial team, including the appointment of our chief commercial officer, who some of you will have met in our previous IMC presentation, alongside a growing team that serve our commercial needs at Four Base Bio. There are several of those employees that are based in the US and another couple of
4:18
Unidentified speaker (speaker_2): those employees that are based here in Europe as well. When we think about the workforce stats, 28% of our scientists hold a bachelor's degree. 43% hold a master's degree, and 12% of us have a PhD as well. So it's a really scientifically minded and focused workforce representing 23 different nationalities.
4:40
Unidentified speaker (UNKNOWN): So
4:40
Unidentified speaker (speaker_2): I mentioned plasmid earlier in the presentation, and really this slide aims to position our synthetic DNA offering against plasma DNA to really decouple that genetic. genomic innovation from manufacturing volatility.
4:53
Unidentified speaker (UNKNOWN): And
4:54
Unidentified speaker (speaker_2): on the left hand side, you can see some of the features or the benefits that we position as a synthetic DNA company versus the traditional and incumbent plasma DNA.
5:03
Unidentified speaker (UNKNOWN): So
5:03
Unidentified speaker (speaker_2): the first of those that I would mention is the cost effectiveness. Our streamlined cell free processes reduce the manufacturing burden and cost, both from an OpEx and a CapEx requirement, which can ultimately reduce our cost. of goods as compared to the incumbent technology. Another very important feature is the flexibility of scale. So when you think about
5:22
Unidentified speaker (speaker_2): conventional plasma DNA manufacturing, there is a use of large-scale bioreactors, which are typically hundreds to thousands of liters with a very complex downstream purification. And one of the benefits of a synthetic DNA manufacturing process is the fact that we can really tailor the batch size depending on what that downstream application is. So, of course, that
5:42
Unidentified speaker (speaker_2): means that we can scale up to serve for those larger programs, whether that's infectious disease or a large genetic medicine consideration. But it also means that we can significantly scale down our manufacturing process and serve medicines that are made for individualized therapies. So some of you will have been familiar with the success of the personalized cancer vaccine news coming from Moderna and
6:02
Unidentified speaker (speaker_2): Merck. And we really believe that our technology is ideally suited for such applications and our GMP offering can serve those individual patients.
6:11
Unidentified speaker (speaker_2): Speed is incredibly important. When we think about plasma DNA, this could be in the range of four to six months to receive a plasma DNA suitable for clinical use. And we're billing for doing that in six to ten weeks. And in the case of personalized cancer vaccines, we believe that. we can deliver that product in less than three weeks.
6:30
Unidentified speaker (UNKNOWN): The
6:30
Unidentified speaker (speaker_2): purity profile of synthetic DNA is significantly enhanced as compared to bacterially derived DNA because there is no risk of host cell contaminants. So that's things like antibiotic contamination, endotoxins, and host cell impurities. And so a lot of clients are choosing to work with four-based bio because of these enhanced purity profiles.
6:52
Unidentified speaker (UNKNOWN): The
6:52
Unidentified speaker (speaker_2): last two points that I would mention on this slide is the complexity of sequences that we can deal
6:57
Unidentified speaker (UNKNOWN): with.
6:57
Unidentified speaker (speaker_2): When we are engaging with some of our partners, they have very complex sequences in their genetic medicines portfolio. And the way that we manufacture DNA means that we're really agnostic to that sequence and independent of length or complexity. The last point that I'll mention is the sustainability and go. angle, which is particularly important for some of our pharma partners who
7:17
Unidentified speaker (speaker_2): are thinking about their own carbon footprint. Traditional plasma DNA is resource and energy intensive with a large environmental footprint. And by switching to synthetic DNA, it's a much more streamlined process with significantly reduced waste streams. So we really believe that our technology is well positioned to meet the requirements of the
7:37
Unidentified speaker (speaker_2): growing genetic medicine. medicines landscape.
7:44
Unidentified speaker (speaker_2): So if we think about the um the positioning of our technology across the breadth of cell and gene therapy, one of the benefits or differentiators as our technology versus our peers is that we have this ability to make different flavors flavours of DNA, which you can see across the top end of the slide. And really those different flavors. of synthetic
8:03
Unidentified speaker (speaker_2): DNA serve respective downstream applications and confer application-specific benefits depending on what that use is, whether it's infectious diseases, personalized medicines, as I mentioned, or gene and cell therapy. You can see a significantly sized and market opportunity associated with all of these downstream use cases. And you can also see a number of
8:23
Unidentified speaker (speaker_2): logos positioned on this slide that are the sorts of clients that Forbase. Fourbase Bio can work
8:28
Unidentified speaker (UNKNOWN): with.
8:33
Unidentified speaker (speaker_2): Moving on to how we can support customers on each stage of their development journey. This can really start as early as preclinical, where we could make something called research grade material that is suitable for their preclinical studies, whether that is in mice or in other animal models for their I and D enabling studies.
8:49
Unidentified speaker (UNKNOWN): And then
8:50
Unidentified speaker (speaker_2): as our partner partners move forward through the clinic, we are able to provide material that is suitable for each phase of manufacturing that they require towards the commercialisation of their drugs. As you might imagine, the dollar value of each opportunity increases as those drugs make their way towards commercialisation in our clients' hands.
9:11
Unidentified speaker (UNKNOWN): So
9:11
Unidentified speaker (speaker_2): now moving on to the commercial update.
9:15
Unidentified speaker (speaker_2): Some of you will be familiar with the recent news flow. We will start here with my appointment in February as CEO, having formerly served as Chief Operating Officer. And in March, we were able to announce a major expansion of our facilities with the intention to move into a new headquarter building here in Cambridge, which we're anticipating to be happening in the new
9:35
Unidentified speaker (speaker_2): year. May brought the launch of a new DNA modality, single-stranded DNA, which aims to serve gene editing applications. And it was also the month in which we signed a clinical supply agreement to support a phase two clinical trial. So this one is quite important to us because it's the first time that we have been able to announce
9:55
Unidentified speaker (speaker_2): a partnership where we're going directly into a phase two clinical trial rather than starting in pre-clinical or high quality and reaching our way through that way. So we're really happy with that, and that project is going very well. In June, we were delighted to appoint Dr. Jeff Collier to our strategic advisory board. For those of you unfamiliar, uh
10:15
Unidentified speaker (speaker_2): Jeff is a poignant leader in the US with respect to mRNA, and we're delighted that that he um wanted to be part of our strategic advisory board. And then in August and September, it was about announcing some of our C DMO partnerships. So in the first instance, we announced our collaboration with Genison, which is an AEV and lentiviral
10:34
Unidentified speaker (speaker_2): viral vector company based in the US, to really combine our service offerings to serve our clients using synthetic DNA to make viral vectors for gene therapies. And similarly, in September, we were able to announce a similar agreement with our partners at TriLink Technology. Technologies, where we're partnering on a leading pharma company's
10:54
Unidentified speaker (speaker_2): phase one cell therapy programme. This is a pharma company that we have previously worked with for another asset. So there's been lots of news flow. We expect more towards the back end of this year and certainly into 2027.
11:09
Unidentified speaker (speaker_3): So thanks, Amy. Now it's a few slides where we'll talk about our go go-to-market to market strategy and how we see the revenues building. On the left, as Amy outlined a couple of slides ago, we really our journey with customers begins around preclinical. Before that, we see the assemblers, companies like Twist and Genscript, for those who are familiar with the
11:29
Unidentified speaker (speaker_3): space, who are making the building blocks that we then assemble and amplify to make our synthetic DNA. So preclinical, clinical, and ultimately in time, we hope to be moving. with our customers into commercial.
11:41
Unidentified speaker (UNKNOWN): As
11:41
Unidentified speaker (speaker_3): Amy showed a few slides ago, we do have a very high quality product. We believe it's very differentiated. Historically, we've been very strong in mRNA, but as you'll see in a few slides, time the different modalities we offer enable us to move into multiple different modalities of these advanced therapies. And we are employing a multi multi-channel channel system,
12:01
Unidentified speaker (speaker_3): both engaging directly, but also for us a network of partnerships. And Amy talked about a couple of those more recent ones with Jennizen and TriLick.
12:12
Unidentified speaker (speaker_3): So in terms of that pillars of the commercial strategy, you'll remember from the picture of the split of the team geographically, we're growing a commercial team that's based predominantly in the US, but we do have people based in the UK and Europe as well. Historically, entry point with customers has been with what Amy
12:32
Unidentified speaker (speaker_3): termed the research use only. So typically in the preclinical phase, so the clients try the product out, they like it, they typically, and we'll see some stats shortly about customer attention. And we hope then to move with them into the clinical pipeline. I think strand number three here. has been a more recent development.
12:52
Unidentified speaker (speaker_3): So this year we were delighted to sign our first deal with a customer who actually switched in the clinic. They started clinical development with plasmid and were unhappy with the quality, and they have now switched over to synthetic DNA. So that was a great deal for us, and we're looking to leverage the commercial team to look at more of those
13:12
Unidentified speaker (speaker_3): opportunities. And finally, I mentioned partnerships. So we have got a great pipeline.
13:19
Unidentified speaker (speaker_3): We disclosed at the half year for the first time the pipeline was more than 60 million of opportunity. But we don't see everything. And we believe by having partnerships with C DMOs, in particular, experts in this in the particular areas we're looking at. So Genison, very strong in viral vectors, trialing trilink very strong. in
13:39
Unidentified speaker (speaker_3): mRNA as examples, that we can leverage their pipelines as well and generate more inbound opportunities. And for those C DMOs, they can offer obviously a broadened technology platform as well for customers who are particularly interested in synthetic DNA.
13:55
Unidentified speaker (speaker_3): Moving on a little bit to the um how we see the revenues growing. So you'll recall those of you who followed the company that in 2025 we had uh the GMP licence granted, and uh up until that point the company was only really able to offer the research use only grade. Now we offer two further flavours, the high quality
14:15
Unidentified speaker (speaker_3): HQ, which um spans the late preclinical into the early clinic, and then full GMP, which spans the later phases of clinical trials. And you'll see on the left here that these opportunities are quite uh different. in terms of the contract sizes we can expect. So the research use only are typically 10 to 20k. We see some smaller, some can go up as much
14:35
Unidentified speaker (speaker_3): as 50 to 100k, but typically in that 10 to 20k range. So clearly to get to seven to eight digits of revenue, then you need a lot of those opportunities. When we start moving into the late preclinical preclinic and the clinic, we see the HQ opportunities typically 250 to 500. 500K. And when we get into GMP, we see those
14:54
Unidentified speaker (speaker_3): beginning really at seven figures and potentially will get much higher as we move, hopefully, with our clients through the clinic and their products go through phase one, phase two, phase three.
15:05
Unidentified speaker (UNKNOWN): On
15:05
Unidentified speaker (speaker_3): the right hand side, we'll see the evolution. If you cast in mind a few slides back, Amy showed the different flavours of uh sympatic sympathetic DNA that we offer that play in different. markets. And I think if you went back two years, the bars here would have been entirely purple, so it would have been uh research use only opportunities. But you'll see actually, in terms of number of opportunities we
15:25
Unidentified speaker (speaker_3): have in the pipeline, um, some of these areas, mRNA, for instance, in the middle, is more than 50% of the opportunities we see in the pipeline would be GMP or high quality opportunities. And we'll show some more stats in a few slides time. but actually really pleased to see growth in viral vectors, gene editing, and DNA as a drug, which
15:45
Unidentified speaker (speaker_3): we think is an exciting new area. So, Amy.
15:49
Unidentified speaker (speaker_2): Thank you. So looking at our H1 2026 stats, we are reporting out on 37 platform adoption evaluations across the first half of the year. And I'm very encouraged with the composition of these opportunities. So on the left hand side, we are working actively with three top 10 pharma companies that are industry leaders that are
16:09
Unidentified speaker (speaker_2): recognizing the benefits of synthetic DNA. As some of you folk may be familiar with, we do have a farmer partner that is in the clinic with our product and soon to be in the clinic with another product. And our expectation is that some of these other partners will follow suit in due course. So very encouraged by those sorts of partners. partnerships that we're going after.
16:29
Unidentified speaker (speaker_2): Biotech still remains to be a very active target for us. These companies are typically a little bit more nimble than our large farmer friends, and we're reporting 19 evaluations each one of this year. On the right hand side, we're focusing on academic centres. So this is quite important for us because in the US, in particular, a lot of these
16:49
Unidentified speaker (speaker_2): academic centres centers are running. their own clinical programs and they have their own GMP and clean room capabilities. So we're very encouraged with some of the partnerships that we're setting up and hope to be able to report on those in in due course. And finally, as Richard alluded to, C DMO partnerships are important to FourBase Bio for a number of reasons. We want to ensure Sure, that the
17:09
Unidentified speaker (speaker_2): downstream manufacturers of drug substances are very familiar with synthetic DNA. and we want to be able to point our customers and our shared customers towards somebody that has that familiarity. But equally, it means that we get a view on perhaps opportunities that poor-based bio wouldn't see as a standalone. So, of course, we mentioned Genison and
17:29
Unidentified speaker (speaker_2): Trilink on the previous slide. We've also recently reported out some very interesting data with Therma Thurma Fisher on our mRNA applications or under and are encouragement. encouraged by Hulk by how all of these C DMO partnerships are progressing.
17:44
Unidentified speaker (UNKNOWN): On
17:44
Unidentified speaker (speaker_2): the left hand side here, we're looking a little bit about the composition of our research use sales year on year, through 23 to 2026. And this is year to date as of the Q3 of 2026. And we think this is quite interesting because we're looking at the evolution of the different types of modalities. that our clients are working
18:04
Unidentified speaker (speaker_2): with. So unsurprisingly, perhaps, RNA remains to be a core focus of Four Based Bio. Our product is very well differentiated there and we're consistently winning. But what is quite encouraging within 2026 is the uptick in viral vector applications that are deploying our synthetic DNA technology, as well as DNA delivery and gene
18:24
Unidentified speaker (speaker_2): editing. We'll show another cut of this data later. in the slides, but of course, one of the KPIs that we're tracking internally is the kind of returning clients and also the respective therapeutic areas that they're working in. So again, and unsurprisingly, there is significant return of customers in that RNA space, mRNA space. And the expectation is that when a
18:44
Unidentified speaker (speaker_2): customer comes back to us for more material, they are progressing through their clinical programs.
18:51
Unidentified speaker (speaker_2): Moving tax a little bit onto a case study with one of our global top five pharma partners. So this particular partner is a multinational company with a very strong incubator program. And actually, um, the this pharma company reached out to Forbase Bio by way of their AAV C DMO with the intention of optimizing their manufacturing
19:11
Unidentified speaker (speaker_2): process for enzymatically produced DNA versus the incumbent technology. Plasmid and to see what those benefits might look like. So, really, this relationship started at the back end of 2024. And throughout the course of 2025, there were a number of studies conducted comparing for-based biosynthetic DNA technology to other synthetic
19:30
Unidentified speaker (speaker_2): technologies alongside plasma DNA. And a number of design of experiment studies were completed to understand how our product would work within their manufacturing. process. And what this partner was able to see was a 30% reduction in DNA mass required as compared to plasma DNA. And they were able to show equivalency of the
19:50
Unidentified speaker (speaker_2): AAV particles that they were able to make independent of that DNA source. So this is quite a significant cost of goods drivers when you're thinking about AEV as a gene therapy. And the pharma company was very happy to see that.
20:03
Unidentified speaker (speaker_2): Interestingly, this has opened the door to a wealth of opportunities within that broader pharma ecosystem. And today we are working with three of that company's incubator programs across the breadth of modalities that 4-based bio feeds into. So not exclusively in viral vectors, but also in gene editing and mRNA. And we are very encouraged by how those evaluations
20:23
Unidentified speaker (speaker_2): are going and what that might mean for 4-based Fort Base bio in 2020. 2027. And finally, the last point that I would mention there is that our MSA negotiations are in finalisation to work directly with this partner.
20:38
Unidentified speaker (UNKNOWN): If
20:38
Unidentified speaker (speaker_2): we take another look at the data of our closed one opportunities to age one of this year, on the left-hand side, we are looking at the value and count depending on the type of client that we're working
20:50
Unidentified speaker (UNKNOWN): with.
20:50
Unidentified speaker (speaker_2): So unsurprisingly, if we look at the by count,
20:55
Unidentified speaker (speaker_2): the biotech partners are comprising the breadth of our count and value when we think about those different opportunities. But what we're also seeing is growth both from pharma and C DMO, which you can see in green and purple respectively, alongside the academic centers. If we move to the right hand side and again focus on the
21:15
Unidentified speaker (speaker_2): count, I think this is quite an interesting cut of data. If anyone was familiar with data that I presented last year or earlier this year, the mRNA section of this was comprising significantly more than it is today. And we're very encouraged by the, let's say, renewed balance of our client base and the growth across those other sectors, including gene editing
21:34
Unidentified speaker (speaker_2): and viral vectors. If we look at value here, you will see. that the mRNA is comprising a significant share of that value. But as Richard mentioned earlier, that is due to the phase two client that we announced earlier this year, with a you know a sizable deal size as compared to some of the other opportunities within the pipeline.
21:56
Unidentified speaker (speaker_2): If we look at the evaluations of synthetic DNA to drive really HQ and GMP considerations. this is how we think about that conversion of our pipeline into revenue generating opportunities. And so on the left hand side, we are looking at the number of projects that we have closed year on year, which is growing. You can see the green bar, which
22:16
Unidentified speaker (speaker_2): represents 2026. This is through to Q3, and we anticipate closing the year end with a higher number of projects versus 2025.
22:25
Unidentified speaker (UNKNOWN): I
22:25
Unidentified speaker (speaker_2): think then if we look at the middle box, this is where it gets quite interesting. So we're looking at our win rate year on year based on the count of opportunities. And what we've been able to see is a significant uptick in that win rate in 2026 and towards the end of 2025, which we attribute to the build-out of our commercial team and the success of the quality of the
22:45
Unidentified speaker (speaker_2): opportunities that they're bringing into the pipeline and ultimately converting into sales orders. Finally, on the right hand side, we are looking at the number of REO opportunities that have now converted into a high quality or GMP opportunity within our pipeline. And as we mentioned earlier, the expectation in one of our
23:04
Unidentified speaker (speaker_2): go-to-market strategies is that we will engage with clients in early stage B clinical and then we will remain sticky and convert through into their GMP opportunities. And we are we're incredibly encouraged. by our 2026 perceived conversion rate sitting at 55%.
23:22
Unidentified speaker (UNKNOWN): So
23:22
Unidentified speaker (speaker_2): I'll hand back over to Richard.
23:25
Unidentified speaker (UNKNOWN): Thanks,
23:26
Unidentified speaker (speaker_3): Amy. So this first slide really encapsulates how we think about the future growth of the business into the midterm. I think in terms of the um GMP facility we have now that we're licensed, we've estimated that we can support around 100 million uh pounds of business, uh high quality GMP business from that facility
23:46
Unidentified speaker (speaker_3): with uh minimal additional CapEx and OPEX. So it's a very flexible facility, clearly uh given the revenues, which I'll come on to talk about shortly. We're not uh utilising a great deal of that facility, but equally it does not cost us a huge amount of money to keep that from moffboard off-board, and we can scale up as we need to. We can actually go beyond that if we were to move to
24:05
Unidentified speaker (speaker_3): 24-7 operations. So this is based on a sort of normal working day. In the middle, our goal in the longer run is to get to a gross margin consistently of at least 75%. Margin does vary across the different product groups, Particularly typically lower at the IUO end, which is a bit more price sensitive, and we see that
24:25
Unidentified speaker (speaker_3): increasing as. we move into HQ and then GMP, where we get the efficiencies of working at larger scale. And finally, on the right hand side, the business has built quite quickly. As Amy mentioned almost right at the beginning, the company is relatively new. We've had to move quickly to get up to speed and to catch up with the
24:45
Unidentified speaker (speaker_3): competition. And so we do expect some of the costs we've had to incur in doing that, in particular, getting the GMP certification an hour finished, and we won't be repeating those. So we would like to see our cost base being in the region of 15 to 16 million sterling in the long run. So I think working backwards from that, you'll see that the
25:05
Unidentified speaker (speaker_3): revenues we need to achieve to break even will be in the region of um just above 20 million sterling. So casting your mind back to the slide where we look at the value of each of the opportunities, we don't need a huge amount of deals to get to that break-even point.
25:21
Unidentified speaker (speaker_3): So just come on to talk a little bit about H1, but before I do that, I just wanted to talk about the cadence of
25:28
Unidentified speaker (speaker_3): pipeline going through to sales orders, going through to revenues. So we disclosed uh for the first time at the half year that the product pipeline, which has grown uh more than eightfold actually now um since we took on board the new commercial team who were really in place around the end of 2025. So we start with the unqualified pipeline, which we
25:48
Unidentified speaker (speaker_3): don't disclose. So all the opportunities which come through our mailbox or that our people pick up on the road where we send proposals, we only reflect in the order book we disclose, or sorry, the pipeline we disclose those which we would classify as qualified. So um clients who are either funded or on the track to being funded, and programs where there's a definite
26:08
Unidentified speaker (speaker_3): plan to get an IND open to run a clinical trial or to move to the next phase of a trial. We will hopefully then be successful in converting those pipeline opportunities into sales orders. And then the sales orders flow through as revenue, um typically as we deliver product. If there's some development revenue. in there that will be
26:28
Unidentified speaker (speaker_3): recognized as the document or report or whatever the output of that process development is. But typically most of the revenue is is recognized when we actually ship the product to the client. That can be up to nine to ten months for GMP product. The additional steps we need to go through for
26:47
Unidentified speaker (speaker_3): GMP. So coming back to the first half performance
26:51
Unidentified speaker (speaker_3): So this is a little bit old now, but just a refresher as we've not talked to investors since we released results. So really a sort of tail of two halves in a way for the first half. The 2025 numbers were really the revenue dominated by sales orders that were closed in 2024. So we saw our revenue
27:11
Unidentified speaker (speaker_3): for the half year of uh just just uh about 1.2 million. Um, sales orders themselves for 2025 were quite weak and continue to be weak actually into the second half of 2025. And that's really was a function of several things. Um, I think it's been well disclosed that there were some challenges in particular with the uh
27:31
Unidentified speaker (speaker_3): mRNA market, where the company had a number of promising programs in the pipeline, uh, which uh sort of evaporated given some of the geopolitics. geopolitical developments in the US. But I think more generally the biotech sector was looking a bit sad in 2025. I think financings were quite low, performance of companies were quite low, and
27:51
Unidentified speaker (speaker_3): that really slowed down decision making as well. So what we see in 2026 in the first half is a very healthy sales order book, so up to around 1.2 million, but revenue really a hangover from 2025, so uh very little sort of what that we carried over from 2025 that we could recognise in the first half of 2026.
28:10
Unidentified speaker (UNKNOWN): Um
28:11
Unidentified speaker (speaker_3): to next slide, thank
28:13
Unidentified speaker (UNKNOWN): you.
28:14
Unidentified speaker (speaker_3): Just to talk a little bit about uh cash. So this is our cash flow evolution over the last few years in the first half. Um, so big fundraising that uh you may recall in 2024. We brought in close to 40. million for expenses. And the operating cash burden has been around about sort of 16
28:34
Unidentified speaker (speaker_3): million pounds a year, give or take, over the last couple of years. Ended the first half with just over 14 million of cash, and then very pleased to announce just a few weeks ago the completion of the 15 million fundraise, and that extends our runway. out into the second half of 2028. So I think in
28:54
Unidentified speaker (speaker_3): terms of uh how we see ourselves deploying those funds on the commercial side, we continue to invest in the uh footprint we have ourselves there. And we would like to see um in this period revenues getting to hopefully double digits, uh recognized recognised revenue, and the pipeline driving that uh is likely to increase further from
29:14
Unidentified speaker (speaker_3): the 60. million that we disclosed at the half year. On the operations side uh to keep the RUA business um running seamlessly we are moving into a new building and we expect to move in there as Amy mentioned uh in uh the first half of next year and that will increase our capacity particularly for the research use
29:34
Unidentified speaker (speaker_3): only uh operations as
29:35
Unidentified speaker (UNKNOWN): well. On
29:36
Unidentified speaker (speaker_3): the R RD and D side there's a flip now so Amy highlighted the very extensive patent estate, which has been built over the last few years. Our focus on the RD now is more D than R. So development particularly focused on turnaround time, which both increases our capacity but also reduces cost of goods, and also
29:56
Unidentified speaker (speaker_3): increasing Increasingly the yield. yields So are looking to recover more products. And both of those aspects will help drive us towards our target cost of goods or gross margin at least of more than 75%. And then GNA supporting that as
30:10
Unidentified speaker (UNKNOWN): well.
30:11
Unidentified speaker (UNKNOWN): So
30:11
Unidentified speaker (speaker_3): I think that ends the formal presentation and happy now to move to questions.
30:18
Unidentified speaker (speaker_1): That's great. Thank you very much indeed, ladies and gentlemen. Please do continue to submit your questions just using the QA tab situated on the right hand corner of the screen. But just while the guys take a few minutes to review the questions submitted already, I'd just like to remind you of recording this presentation along with the QA and the slides will be available via the Investor Meet Company dashboard. Um Amy, if it's all right, I'm just going to bring back up the camera uh for the
30:38
Unidentified speaker (speaker_1): QA. Uh there we go. Um perfect. On the right hand side, hopefully you can see the questions. Thank you to you uh to those on the call for your engagement. If I may just hand back to you, Amy, if you could uh read out the questions where it's appropriate to do so and I'll pick up from you at
30:50
Unidentified speaker (UNKNOWN): the end.
30:51
Unidentified speaker (speaker_2): Yeah, that's great. So we've got Matt H. um asking can our existing manufacturing facility support substantial revenue growth or will further investment be required? So I think Richard commented on that a little bit. We do not um perceive significant investment to be required into that current manufacturing facility. And one of the benefits of our manufacturing process is
31:11
Unidentified speaker (speaker_2): from a kind of CapEx and OPEX consideration, it is incredibly small with respect to footprint. And so the seven suites that we have there are more than suitable to fulfill the orders that we have today and their relative scale, but also those later stage opportunities that are going to require much more DNA than what we're making today. So we do not believe that that
31:31
Unidentified speaker (speaker_2): facility requires substantial further investment. And we believe, as as Richard mentioned, that out of the current facility we can be generating over 100 million of. revenue.
31:41
Unidentified speaker (speaker_0): Go ahead.
31:42
Unidentified speaker (speaker_3): So second question from uh Matt. Uh, how long does it typically take to turn an initial customer inquiry into a paying customer and then into repeat orders?
31:52
Unidentified speaker (UNKNOWN): Yeah,
31:53
Unidentified speaker (speaker_2): so maybe I can start there, Matt, and I'll give you an answer that you don't like. It really depends. Um, in some cases, I mean, generally speaking, over CDMO, sales cycles are incredibly long. And if you ask asked another larger CDMO the same question, I think they would be reporting out anywhere between 12 to 18 months from that initial point of contact into something quite substantial. That being
32:13
Unidentified speaker (speaker_2): said, there are some exceptions. So I think a lot of our current customer base have already evaluated our research grade opportunity material and compared that to the incumbent technology Plasmid with very successful results. And so that's the opportunity where people can start to move more quickly. We actually have an opportunity that is in manufacturing at the moment that closed within a couple of
32:33
Unidentified speaker (speaker_2): months rather than that kind of nine to 12 months that I mentioned. So it really depends. And this is a KPI that Richard and I assess to try and shorten that sales cycle and make sure that from a you know holistic perspective, including contracting, including audits, including all of those agreements, that we can really streamline that and bring ourselves to close our revenue much. much more quickly.
32:51
Unidentified speaker (speaker_3): Yes, and just to add to that, um, we are starting to employ a key account management strategy, um, in particular for the larger farmers. And you'll have seen at the beginning we're working with six out of the ten now at various stages, and also the larger biotechs uh who typically move a little bit more slowly. So that key account management will be early engagement through the
33:11
Unidentified speaker (speaker_3): RUO IUO to get the technical people bought in. It will be um engaging the quality people, which could be an audit, and it will be engaging their legal teams, which is the one that scares me the most. Getting MSAs in place, which you know can take a surprisingly long time. So once we have these in place, actually adding new opportunities can
33:31
Unidentified speaker (speaker_3): be very quick and you know, really as quick as the customer wants to move.
33:35
Unidentified speaker (speaker_2): Yeah. The last point that I would mention there actually is in this field of personal. personalized cancer vaccines. So I think that kind of turns everything else in its head because these patients are individual patients that are, you know, late-stage cancer patients that are waiting for a therapy, and we need to move incredibly quickly there. The expectation from some of our partners is that we're going to be delivering that material in less than four
33:54
Unidentified speaker (speaker_2): weeks. And so how we envision that is that a partner would contract with Four-Base Bio for a broader clinical trial and then as a and when they receive a patient onto their trial, we need to execute incredibly quickly. And then the recognized revenue profile of that sort of opportunity versus a standard opportunity for 4-based bio is fundamentally different
34:15
Unidentified speaker (speaker_2): because it will be on a per-batch basis. So that's quite an exciting opportunity. I mentioned already my personal excitement and how why I think that we can serve that market.
34:25
Unidentified speaker (speaker_2): Um, one more from Matt H. Richard, this one's for you, I think.
34:29
Unidentified speaker (speaker_3): Yep. So uh what level of annual revenue would allow the business to become cash flow positive? So assuming we can meet our uh gross margin target of 75% and we can keep the cost space to around 15, 16 million, uh, we'll be around 21, 22 million of revenue. So um thinking back to the different size of the
34:49
Unidentified speaker (speaker_3): deals, so that would be um just over 20 um GMP deals, so it's not a huge amount. Um that's based on those being early stage. Uh we do see opportunities at later stage, which go to sort of one, three, five, even up to seven million for opportunities. So you can see actually that uh if we were very lucky and would you know it would be a big step up for the company,
35:09
Unidentified speaker (speaker_3): we had three of those really big deals, and actually that would turn the needle for us to be to become cash flow. positive. One more thing just to mention on cash flow, it wasn't the question that was asked, but I'll answer it anyway. Is um typically we do get a chunk of money up front from customers. So although the revenue uh can only be recognised, and apologise for the accounting profession
35:29
Unidentified speaker (speaker_3): uh when we deliver the product, um, we actually typically see um 30 to 50 percent of the cash uh can come up front. So we're typically cash flow positive. on any given opportunity that we're developing for a client.
35:45
Unidentified speaker (speaker_2): That's great. John E, hello. The question from John is that in the event that one of our partners brings an approved drug to the market in the US, will the company be identified in any of the documentation that the FDA might publish in connection with an approval? The expectation is yes. So we have a drug uh master. file on file with the FDA. And
36:05
Unidentified speaker (speaker_2): as our clients move towards commercialization of their programs for and for Base Bio will be more and more involved. In fact, we would anticipate an audit from the FDA in that case. So yes, we we hope and we expect that we will be able to announce our integration into some of those pharma programs that are moving towards commercial.
36:23
Unidentified speaker (UNKNOWN): And
36:23
Unidentified speaker (speaker_3): then second question, which is a great one because I've asked the same question internally. For those projects that you didn't win, is there a consistent single winner or are there multiple other competitors that you compete with in early stages?
36:35
Unidentified speaker (UNKNOWN): Yeah,
36:35
Unidentified speaker (speaker_2): so maybe I can answer that. So, John, when when we're competing against other players in this space, we we really tend to win on the product quality. I think when we're thinking about opportunities that we have lost, typically they are to do with funding competition. constraints of the customer, later delays of programs rather than a kind of
36:55
Unidentified speaker (speaker_2): consistent reason of why a four-based bio lost an opportunity. But we are incredibly encouraged about how our product performs in our customers' hands and really the feedback of our product has been has been glowing. So we're we're super excited about that.
37:09
Unidentified speaker (speaker_2): Um Another question
37:14
Unidentified speaker (speaker_2): here. Richard.
37:15
Unidentified speaker (speaker_3): Yeah, so a financial question. Um, please explain how you reconcile your guidance for a yearly cost base in the region of £15 million with first half 2026 overheads close to nine million. So I think there's a couple of different aspects to that. So um we do see as we move from the uh research
37:35
Unidentified speaker (speaker_3): phase to more of a development phase, um naturally there's always some sort of cycling of people who choose to go off and do different things, and you know, those won't necessarily be replaced on a like for like basis. I think a more significant component was the costs of getting the GMP license, which I think are quite uh
37:55
Unidentified speaker (speaker_3): frightening when you look at them, but that's a one one-off, off, and now that's done, that's done, so we won't repeat that as well. And I think generally um, as a team that then we've we've had to invest to move quickly. And you know, we're always looking for efficiencies in the cost space. So we feel quite confident that uh we will be able to bring the cost space down, and notwithstanding the fact that
38:15
Unidentified speaker (speaker_3): obviously there is uh inflation as well. So um I mean in fact we you know we sort of go just going through our annual budgeting exercise and feel quite confident that we can uh meet the sort of um the target we set. ourselves.
38:27
Unidentified speaker (speaker_2): Yeah, Bruno, the the last point that I would mention there in in addition to the very significantly reduced consultant spend that we've previously engaged with, now that we have our certification, it's also on the on the IP as well. So you know there was very prolific IP felling across the breadth of our portfolio and now we're in the stages of prosecution there. So we we feel confident that we
38:47
Unidentified speaker (speaker_2): can bring bring ourselves down towards that set steady state of 15 fifteen to sixteen million.
38:52
Unidentified speaker (speaker_1): That's great. Richard, Amy, I think you've taken all the questions for investors. Thank you to everybody once again for your engagement this afternoon. Amy, Richard, I know investor feedback is important to you guys. I'll shortly redirect those on the call to to give you their thoughts and expectations. But maybe uh Amy, I could come back to you for a couple of closing comments.
39:10
Unidentified speaker (speaker_2): Yes, um obviously uh we are very delighted uh to have announced the the recent capital raise into the business. We feel increasingly excited about the role Forebase Bio can can play in the future of genetic medicines and and very confident in in 2027. So thank you all for participating in today and we look forward to the feedback.
39:27
Unidentified speaker (speaker_1): That is great. Amy Richard, thank you once again. Could I please ask investors not to close this session as we'll now automatically redirect you for your feedback? Thank you for your time once again and enjoy the rest of
39:37
Unidentified speaker (UNKNOWN): the
39:54
Unidentified speaker (speaker_0): The best part is it's free. Our mission is to give retail investors like you the same access and information. as institutional investors. Visit investormeetcompany.com today to follow the companies you're interested in.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from Investor Meet Company - Audio Archive

All insights